Citations

Clear

940 citation(s) found for "Olson, JA".

Automated pupillometry for detection of delirium in surgical intensive care patients
Míča, Patrik, Lukeš, Marek, Pokorna, Andrea, Hruda, Jan , Olson, Lyle, Cundrle, I, Pokorná, Andrea, Svoboda, Michal , Čundrle, Ivan

Mayo Clinic

Frontiers in Medicine | June 4, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fmed.2026.1822468 | PMID 42328550 Get It

Background Delirium is a frequent and serious complication in critically ill patients and associated with adverse outcomes. Automated pupillometry has emerged as a potential diagnostic tool for the detection of delirium. However, pupillometric parameters are also influenced by pain, potentially confounding their relationship to delirium. The aim of this study was to evaluate the association between automated pupillometry parameters and delirium in patients with high risk of pain (surgical patients) admitted to intensive care units (ICU). Methods This prospective multicenter observational study included adult surgical patients admitted to an ICU between April 2023 and August 2025. Delirium was assessed every 6 h after admission using CAM-ICU. Automated pupillometry together with pain intensity scores (VAS, CPOT, BPS) were performed concurrent with CAM-ICU. To account for repeated measurements within individual patients, a generalized linear mixed-effects model (GLMM) with patient as a random effect was used to evaluate the association between pupillometric parameters and diagnosed delirium. Results Forty-nine patients were included, yielding 417 measurements, of which 48 (12%) were done in patients who were simultaneously CAM-ICU positive. Among pupillometric variables, only average pupillary latency (LAT avg) was significantly shorter in patients with delirium ( p = 0.01). In the mixed-effects model adjusted for sedation depth, level of consciousness, and pain intensity, LAT avg. was independently associated with delirium (OR 1.55 per 0.01; 95% CI 1.13–2.13; p = 0.007). Conclusion In surgical ICU patients, shortened pupillary light reflex latency is associated with delirium. Automated pupillometry may serve as a useful tool for detection of delirium in this population. Clinical trial registration https://clinicaltrials.gov/study/ Identifier: NCT05811208.
Postpartum-associated breast cancer: Patient outcomes analysis.
Idossa, Damé, Ruddy, Kathryn Jean, Vierkant, Robert A., Larson, Nicole, Sherman, Mark E., Couch, Fergus J., Olson, Janet E., Idossa, Damé , Ruddy, Kathryn J. , Vierkant, Robert A., Larson, Nicole L. , Cathcart-Rake, Elizabeth , Sherman, Mark E. , Couch, Fergus J. , Olson, Janet E.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e12697 Get It

e12697 Background: Postpartum-associated breast cancer (PABC) has been defined clinically as breast cancer (BC) diagnosed within the first 5 years of the most recent birth. Though generally rare, incidence rates are increasing in conjunction with delayed childbearing and older maternal age at first birth. Currently, there are limited data regarding serial patient-reported outcomes in this patient population compared to non-PABC patients. Methods: Patients with PABC from the Mayo Clinic Breast Disease Registry who completed baseline, 2, and 4-year surveys were matched 1:1 to BC patients whose cancers occurred more than 5 years after their most recent birth (or in the setting of nulliparity) based on age, clinical stage, treatment received, and tumor subtype. Survey results from the Patient Health Questionnaire-2 (PHQ-2), Patient-Reported Outcomes Measurement Information System-10 (PROMIS-10), and Impact of Event Scale-Revised (IES-R) collected at approximately two and four years after diagnosis were compared between PABC and non-PABC patients. Univariable analyses used Wilcoxon rank sum tests, whereas multivariable analyses employed linear regression models adjusting for potential confounding effects. Results: A total of 222 individuals were included (111 with PABC). A higher proportion of individuals in the PABC cohort were married compared to the non-PABC cohort (80% vs. 42%, p < 0.001); otherwise, the groups were well-balanced across multiple categories, including age, gender, race/ethnicity, menopausal status, and germline mutation status. In univariable analyses, the Year 2 composite PHQ-2 score was significantly worse among individuals with non-PABC (p = 0.04), and the non-PABC cohort reported greater difficulty with sleep (p = 0.03) as measured by IES-R at Year 4. Both associations attenuated in a multivariable analysis controlling for marital status. In marital status-adjusted analyses of Year 4 survey results, PABC participants reported greater difficulty in carrying out social activities but were less likely to report emotional distress as evaluated by PROMIS-10 (compared with non-PABC participants). No other variables were significant univariably or multivariably (p > 0.05). Conclusions: In general, quality of life is similar among survivors of PABC compared to those diagnosed with breast cancer outside the postpartum period (or when nulliparous). However, our findings reveal that individuals with PABC are less likely to experience emotional distress 2 and 4 years after the BC diagnosis, which is unexpected, given that postpartum patients typically report higher levels of distress compared to their non-postpartum counterparts. Further investigation into these findings is warranted.
Development of an endometrial cancer test from a vaginal swab.
Gagrat, Bridget Z. , Camardo, Mark, Slettedahl, Seth, Lemens, Maureen, Taylor, William R., Harrington, Shariska, Zella, Julia, Kielar-Grevstad, Elle, Olson, Marilyn, Bakkum‐Gamez, Jamie N. , Krockenberger, Martin , Kisiel, John B. , Slettedahl, Seth W. , Lemens, Maureen A. , Kielar‐Grevstad, Elle, Beer, Tomasz M. , Olson, Marilyn

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 5624-5624

10.1200/jco.2026.44.16_suppl.5624 Get It

5624 Background: Endometrial cancer (EC) is the most common gynecologic cancer and abnormal uterine bleeding (AUB) is the predominant presenting symptom. While <10% of AUB represents underlying EC, endometrial sampling is currently required to rule out EC. To develop an alternative, non-invasive rule-out strategy, we aimed to refine a previously reported EC-associated methylated DNA marker (MDM) panel in vaginal swabs. Methods: Patients ≥18 years old with AUB who met ACOG recommendations for endometrial sampling and those undergoing a hysterectomy for biopsy-proven EC or atypical hyperplasia (AH) were prospectively enrolled in a multicenter cohort study. A vaginal fluid specimen was collected via swab by a provider during a speculum exam. DNA was extracted from samples and bisulfite treated, followed by a target and signal amplification method to detect 8 previously identified MDMs. The cross-validated EC classification model used the mean of standardized MDMs. Clinical classification of benign endometrium (BE), EC, and AH was based on central pathology review. EC diagnoses were based on hysterectomy specimens. Endometrioid and mucinous constituted type 1 EC; serous, carcinosarcoma, clear cell, and mixed histology ECs were collectively analyzed as type 2. Results: Of 693 participants enrolled, 670 were evaluable with valid results: 524 in the AUB cohort and 146 in the suspected EC cohort. Within the AUB cohort, 16 had EC or AH. The final analysis cohort included 508 BE, 156 EC, and 6 AH. Of the evaluable participants 20% identified as Black, 3% Asian or Pacific Islander, 75% White, and 3% Other; 7% reported Hispanic ethnicity. Median age was 66 and 50 years for EC and BE AUB, respectively; 80% of those with EC and 43% with benign AUB reported being postmenopausal. Among participants with EC, 102 (65%), 17 (11%), 30 (19%), 6 (4%) were stage I, II, III, and IV, respectively; one EC was unstaged. Type 2 EC accounted for 42 (27%) of all EC cases. A 4-MDM panel yielded an AUC of 0.97 (0.96-0.99, 95% CI) for EC; models with 5-8 MDMs gave identical performance. All-stage EC sensitivity was 97, 97, 96, 95, and 92% at specificities ranging from 75, 80, 85, 90, and 95%, respectively. At the 85% (82-88%) specificity threshold, sensitivities across EC stage, type, and age were consistently high (Table). Sensitivity for AH was 33% (10-70%). Conclusions: An MDM panel demonstrated high sensitivity for EC across stage and EC type, supporting the potential for a non-invasive vaginal swab-based test to rule out EC. Future studies are necessary to finalize the panel and algorithm, prior to validating the test. Clinical trial information: NCT06294886 . EC Sensitivity (%, 95% CI) at 85% Specificity All Stages (n=156)* 96 (92-98) Stage I (n=102) 94 (88 - 97) II (n=17) 100 (82 - 100) III (n=30) 100 (89 - 100) IV (n=6) 100 (61 - 100) Type 1 (n=114) 95 (89 - 98) 2 (n=42) 100 (92 -100) Age ≤ 66 yrs (n=86) 95 (89 - 98) > 66 (n=70) 97 (90 - 99) *n=1 EC was un-staged.
Adjuvant endocrine therapy omission in ER-positive breast cancer treated with neoadjuvant chemotherapy.
Choong, Grace M. , Olson, Carrie, Goetz, M. P., Hoskin, Tanya L. , Olson, Carrie A., Ingle, James N. , Boughey, Judy C. , Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 525-525

10.1200/jco.2026.44.16_suppl.525 Get It

525 Background: Adjuvant endocrine therapy (ET) decreases breast cancer (BC) recurrence and improves overall survival (OS) for patients (pts) with estrogen receptor positive (ER+) BC. Omission of adjuvant ET and nonadherence are major issues contributing to worse clinical outcomes. Recent data suggest that the number of pts who omit adjuvant ET may be increasing in Europe [1]. These data have yet to be evaluated in the U.S. We previously reported data from the National Cancer Database (NCDB) that ET omission was more likely in pts with ER+/HER2+ disease who achieved a pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) [2]. Herein we report an updated analysis with a larger cohort designed to examine trends in ET omission over time and the impact on OS in a group of pts at high risk of recurrence. Methods: The NCDB was queried from 2010-2022 for pts with stage I-III ER+BC treated with NAC and surgery. pCR was defined as ypT0, ypN0. Use of adjuvant ET and the impact of adjuvant ET omission on OS in pts with and without pCR were assessed separately based on HER2 status. Adjuvant ET initiation by 1 year was summarized using the cumulative incidence estimate to account for the competing risk of death. OS was analyzed with ET as a time-dependent covariate using multivariable Cox proportional hazards regression. Results: We identified 130,438 pts with ER+BC (78,778 ER+/HER2-, 51,660 ER+/HER2+) who received NAC. Median follow-up was 5 years. Overall, pCR was achieved in 10.0% of ER+/HER2- and 35.9% of ER+/HER2+. On multivariable analysis, ET omission was significantly associated with worse OS in pts with residual disease (RD) [ER+/HER2- (HR 1.80 p<0.001) ER+/HER2+ (HR 1.66 p<0.001] and in those with a pCR [ER+/HER2- (HR 1.38 p=0.002) ER+/HER2+ (HR 1.42 p<0.001)]. Between 2010-2017, adjuvant ET omission was stable, with approximately 10.0% of pts not having initiated ET by 1 year after surgery. The proportion of pts omitting ET overall increased thereafter to 12.9% in 2018, rising to 24.4% in 2022. A sharp increase in ET omission was observed 2021-2022 in ER+/HER2- BC who achieved pCR, with 42.4% omitting ET compared to 25.1% for 2018-2020 and 18.8% for 2010-2017 (p<0.001). Adjuvant ET omission showed more modest but significant increases for other subgroups (p<0.001): ER+/HER2- with RD (8.5% 2010-2017, 12.3% 2018-2020, 18.7% 2021-2022), ER+/HER2+ with pCR (15.1% 2010-2017, 14.0% 2018-2020, 24.4% 2021-2022), and ER+/HER2+ with RD (9.5% 2010-2017, 12.5% 2018-2020, 22.2% 2021-2022). Conclusions: In ER+BC treated with NAC, omission of ET is increasing over time and associated with a higher risk of death, regardless of HER2, RD, or pCR status. These findings have substantial public health implications as they may result in a reversal of the 4-decade improvements in breast cancer mortality. Additional intervention is critical to improve adherence to guidelines. [1] Verreck et al. Breast 2025 [2] Choong et al. SABCS 2022.
Hypercontractile phenotype at rest in chronic coronary syndromes predicts impaired functional reserve and increased mortality
Ciampi, Q C Quirino, Cortigiani, Lauro , Zagatina, Angela, Padang, Ratnasari , Kane, Garvan C, Villarraga, Hector R, Arruda‐Olson, Adelaide M. , Kalinina, Elena, Lowenstein, Jorge, Haber, Diego M Lowenstein, Marconi, Sofia, Boshchenko, Alla, Rodriguez-Zanella, Hugo, Wierzbowska-Drabik, Karina, Kasprzak, J D, Merli, Elisa , Djordjevic-Dikic, Ana, Amor, Miguel, Saad, Ariel, Safarova, Ayten, Timofeeva, T. N. , Vazquez, J P, Rigo, Fausto, Nikolic, Aleksandra, Ostojic, M, Kovacevic-Preradovic, Tamara, Cerracchio, Emma, Tripepi, Giovanni Luigi, Yin, Lixue , Villari, B, Pellikka, Patricia A, Picano, Eugenio, Zagatina, A , Ciampi, Quirino , Wierzbowska‐Drabik, Karina , Kasprzak, Jarosław D. , Ciampi, Quirino , Cortigiani, Lauro , Zagatina, Angela , Padang, Ratnasari , Villarraga, Hector R , Ryabova, Tamara , Rodriguez-Zanella, Hugo , Gaibazzi, Nicola , Pepi, Mauro , Wierzbowska-Drabik, Karina , Kasprzak, Jaroslaw D , Wang, Yi , Kane, Garvan C. , Villarraga, Hector R. , Kalinina, Elena , Lowenstein, Jorge , Arbucci, Rosina , Haber, Diego M. Lowenstein, Čelutkienė, Jelena , Boshchenko, A , Rodríguez‐Zanella, Hugo , Bursi, Francesca , Đorđević-Dikić, Ana, Amor, Miguel , Haberka, Maciej , Safarova, Ayten, Nikolic, Aleksandra, Gaibazzi, Nicola , Kovačević-Preradović, Tamara , Tripepi, Giovanni Luigi , Villari, Bruno, Carerj, Scipione , Pellikka, Patricia A. , Picano, Eugenio

Mayo Clinic

ESC Heart Failure | May 23, 2026 | Volume: 13 | Issue: 4 | Pages: No page available

10.1093/eschf/xvag151 | PMID 42249823 Get It

Abstract Introduction Transthoracic echocardiography (TTE) identifies a hypercontractile phenotype (HP) in chronic coronary syndromes (CCS), characterized by elevated resting left ventricular (LV) elastance (force = systolic blood pressure/end-systolic volume). To evaluate the prognostic significance and functional correlates of HP. Methods In a prospective multicentre study, 10 677 patients with CCS underwent resting TTE to assess LV ejection fraction (EF), stroke volume, and force by quantitative volumetric echocardiography. All patients were followed for the endpoint of all-cause mortality. In a subset of 5834 patients, stress echocardiography (exercise or dobutamine) was performed for LV contractile reserve and heart rate reserve. Results Patients were stratified into Force quintiles (Q1–Q5). Patients with hypercontractile phenotype exhibited lower stroke volume at rest (Q5 = 34.8 ± 12.3 vs Q1–Q4 = 57.4 ± 19.1 mL; P &lt; .01) and higher EF at rest (Q5 = 64.8 ± 6.9% vs Q1–Q4 = 58.1 ± 8.7%, P &lt; .01). During a median follow-up of 24 months (interquartile range = 12–40 months), 509 deaths occurred. The exposure-adjusted death rate was lowest in Q3 (3.53–4.51 mmHg/mL; 1.03 per 100 person/years) and higher in Q1 (≤2.62 mmHg/mL, 2.88), Q2 (2.63–3.52 mmHg/mL, 1.86), Q4 (4.52–6.11 mmHg/mL, 1.56), and Q5 (HP, &gt;6.11 mmHg/mL; 1.88; P &lt; .0001 vs Q1 and Q3). Multivariable analysis identified HP (Q5; HR 1.531 vs Q3, 95% CI 1.116–2.099; P = .006) and EF (HR 0.963, 95% CI 0.953–0.972; P &lt; .0001) as independent predictors of death. During exercise or dobutamine stress, HP showed reduced LV contractile reserve (ΔEF: Q5 = 4.3 ± 9.4% vs Q1–Q4 = 7.0 ± 9.3%; P &lt; .001) and blunted heart rate reserve (Q5 = 1.77 ± 0.33 vs Q1–Q4 = 1.85 ± 0.39; P &lt; .01). All patients with force-based LV contractile reserve &gt;4.1 (present in 185, 3.2% of the population) survived. Conclusion Patients with CCS with HP assessed by resting TTE demonstrate higher mortality and multilayered functional impairment, including reduced LV contractile and chronotropic reserves. Hypercontractile phenotype improved the prediction of mortality by EF. A ‘stronger’ heart is, in fact, functionally and prognostically weaker.
Circadian variation of post-operative complications in lung resection surgery
Lukeš, Marek, Hruda, Jan , Chovanec, Zdeněk , Olson, Lyle, Cundrle, I, Brat, Kristián , Svoboda, Michal , Čundrle, Ivan

Mayo Clinic

Frontiers in Physiology | May 20, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fphys.2026.1818583 | PMID 42245833 Get It

Introduction Studies have revealed circadian rhythms affect many organ systems and time of injury can impact healing, lung function, and inflammation. We hypothesized operative time may impact post-operative risk. Accordingly, the aim of this study was to compare post-operative complications in patients whose surgery started and finished before 12pm (Group 1); after 12pm (Group 2); and started before 12pm and finished after 12pm (Group 3). Methods Patients from two previous prospective studies were included in this post-hoc analysis. Inclusion criteria were indication for lung resection surgery (confirmed or highly suspicious tumor), age ≥18 and ability to undergo cardiopulmonary exercise testing (CPET). Exclusion criterion was inability to perform surgery (either low predicted postoperative oxygen consumption or inoperability). All patients underwent pre-operative CPET and spirometry. Post-operative pulmonary (PPC) and cardiovascular complications (PCC) were prospectively assessed from the hospital stay up to 30 days. Results Data from 497 patients were analyzed. On comparison of groups, there were differences in BMI (highest in Group 3), surgery duration (lowest in Group 1) and frequency of lobectomies (lowest in Group 1). Incidence of PPC was lowest in Group 1 (n=17; 9%) compared to n=17 (21%) in Group 2 and n=37 (17%) in Group 3 (p=0.01). Incidence of PCC was lowest in Group 1 n=25 (13%) compared to n=19 (23%) in Group 2 and n=46 (21%) in Group 3 (p=0.05). Multivariate logistic regression adjusted for confounders (BMI, surgery duration and lobectomy) showed time of surgery after 12pm was independently associated with PPC with OR = 2.17 (95% CI 1.07-4.41); p=0.03. Conclusion Time of surgery may impact the incidence of PPC in lung resection surgery patients with highest risk in patients undergoing the surgery after 12pm.
B46-23 A Phantom Mediastinal Mass -Pericardial Recess
Onkaramurthy, N Jayachamarajapura, Farahani, L, White, D, Olson, E J, Scrodin, M Dulohery, Onkaramurthy, Neema Jayachamarajapura , Scrodin, M. Dulohery

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.3438 Get It

Abstract Introduction Mediastinal masses encompass broad differentials of reactive, inflammatory, infectious or neoplastic etiology. In the background of extra thoracic malignancy, it raises a high suspicion for primary cancer or metastatic lymphadenopathy. However, a benign anatomical variant can mimic these findings and lead to unnecessary diagnostic procedures and patient anxiety. Recognizing mimickers becomes crucial in avoiding misdiagnosis and overtreatment. Case A 50-year-old woman with no significant past medical history presented with a two-day history of headache, associated with cough, orthopnea and lower extremity edema. Vital signs were significant for elevated blood pressure at 199/107 mm Hg. Laboratory findings noted a markedly elevated B-type natriuretic peptide (19,000 pg/mL), increased serum creatinine (1.4 mg/dL from baseline 0.7 mg/dL) and proteinuria. Chest X-ray revealed pulmonary vascular congestion. Autoimmune serologies were positive for antinuclear antibody (titer 1:2560), ribonucleoprotein antibody, and RNA polymerase III antibody. Renal biopsy confirmed scleroderma renal crisis. She was treated for hypertensive emergency secondary to scleroderma renal crisis. Further evaluation for elevated total protein revealed monoclonal gammopathy on electrophoresis and 30% plasma cells on bone marrow biopsy, consistent with smoldering multiple myeloma. A chest computed tomography scan incidentally identified a 4 × 3 cm lobular right paratracheal mass. Tissue biopsy was requested to exclude plasmacytoma. Bronchoscopy with endobronchial ultrasound revealed a large hypoechoic paratracheal lesion. Biopsy was aborted due to its cystic appearance and risk of airway flooding. Subsequent magnetic resonance imaging was obtained for tissue characterization which delineated the mass as a thin walled, fluid filled structure communicating with the superior aortic recess, consistent with a high riding superior pericardial recess which is a benign anatomical variant. She was discharged with plans for outpatient multidisciplinary follow up, including pulmonary evaluation for interstitial lung disease surveillance. Discussion High riding pericardial recess is a benign anatomical variant which can closely mimic pathologic masses or lymphadenopathy on cross sectional imaging. Key is identification of probable communication with the superior aortic recess associated with fluid attenuation. Knowledge of anatomy, comprehensive multimodal imaging review, and multidisciplinary discussion are key to prevent unnecessary investigation of mediastinal abnormalities. This abstract is funded by: None
Lynch Syndrome in the General Population: Clinical Phenotype of PMS2 Pathogenic Variants
Barrett, Kelly M. Schiabor , Hajek, Catherine, Lu, James T. , Lynch, Kate , Sturm, Amy C., Haldeman‐Englert, Chad , Stoller, Douglas , Chapman, Christopher N., Chahal, C. Anwar A. , Judge, Daniel P., Olson, Douglas A., Lee, William , Cirulli, Elizabeth T., Chahal, Choudhary Anwar A , Hajek, Catherine A. , Lynch, Kate, Senter, Leigha , Sturm, Amy C. , Stoller, Douglas A. , Judge, Daniel P. , Olson, Douglas A., Grzymski, Joseph J. , Cirulli, Elizabeth T. , Bolze, Alexandre

Mayo Clinic

JCO Oncology Advances | May 12, 2026 | Volume: 3 | Issue: 2 | Pages: No page available

10.1200/oa-25-00075 Get It

PURPOSE The Lynch syndrome (LS) genes, MLH1 , MSH2 , MSH6 , and PMS2 , are considered to be some of the highest-priority genes to be tested for population genomic screening, with the aim to prevent and detect cancers early in those with a higher risk for such diagnoses. The objective of this study was to determine the risk of cancer associated with pathogenic variants in MLH1 , MSH2 , MSH6 , or PMS2 in the general population to build evidence-based guidelines for population genomic screening METHODS This retrospective case-control study uses Helix Research Network data from 230,159 participants across nine US health systems. Variant interpretation was performed following the American College of Medical Genetics and Association for Molecular Pathology guidelines. Clinical diagnoses were identified from electronic health records and claims data for 11 cancer types associated with LS, including colorectal and endometrial cancers. RESULTS Individuals with pathogenic variants in MLH1 , MSH2 , and MSH6 showed substantial risk for LS-related cancers compared with those without pathogenic variants. Conversely, individuals with pathogenic variants in PMS2 had no increase in risk for all 11 LS-associated cancers with hazard ratio (HR) of 1.0 (95% CI, 0.6 to 1.8) compared with those without a pathogenic variant. There was a small increase in risk when restricting the analysis to colorectal cancer with an HR of 3.5 (1.7-7.4). This increase in colorectal cancer risk was predominantly observed after age 60 years, 10 years after US Preventive Services Task Force guidelines recommend starting colonoscopies for the average population. Up to age 60 years, 2.6% of individuals with PMS2 pathogenic variants were diagnosed with colorectal cancer, closer to the general population (0.7%) than those with MLH1 (37.3%), MSH2 (28.9%), or MSH6 (6.7%) pathogenic variants. For 100,000 individuals screened for PMS2 , 854 additional colonoscopies would be performed, which would prevent or detect early 3.2 colorectal cancers. CONCLUSION This analysis across nine health systems highlights the clinical phenotypes of PMS2 pathogenic germline variants in the entire population.
0650 Impact of Comorbid Insomnia and Sleep Apnea (COMISA) on Hypoglossal Nerve Stimulator Outcomes
Hamza, Amina, Olson, Michael, Junna, Mithri, OLSON, E, Morgenthaler, TI, Hamza, Amina, Junna, Mithri R.

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A289-A289

10.1093/sleep/zsag091.0649 Get It

Abstract Introduction Hypoglossal nerve stimulation (HGNS) is an effective therapy for moderate-to-severe obstructive sleep apnea (OSA) in patients intolerant of positive airway pressure. Comorbid insomnia (COMISA) is common and may shape their engagement. Despite reports of improved insomnia symptoms, real-world data suggest reduced adherence and increased support needs. This study evaluated the impact of COMISA on HGNS therapy patterns and outcomes. Methods We conducted a retrospective cohort study of 46 adults with OSA who underwent HGNS implantation at Mayo Clinic Rochester between July 2020 and August 2025. Patients were categorized as OSA alone or COMISA based on pre-implantation data, including documented insomnia diagnosis, insomnia severity index score ≥15, sleep initiation or maintenance complaints, hypnotic or melatonin use, participation in cognitive behavioral therapy for insomnia, or an insomnia care plan within one year prior to activation. We collected HGNS adherence metrics (30-day average nightly use, nightly pauses, percent nights used) at 1, 3, 6, and 12 months; non-visit HGNS-related clinical encounters at 6 and 12 months; and pre- and post-activation AHI from polysomnography or home sleep apnea testing. Longitudinal outcomes were analyzed using mixed-effects models with fixed effects for time and COMISA status and a random intercept for patient. Results The cohort was 54% male and 98% White, with median age 66 years and BMI 31 kg/m2 (24–34). Median pre-implant AHI was 27 (19–40), and 30 patients (65%) had COMISA. Median nightly HGNS use declined from 7.8 to 6.6 hours from 1 to 12 months; mixed-effects modeling confirmed significant decreases over time (p≤0.03). Median nightly therapy pauses increased from 0.1 to 0.5, and median non-visit clinical encounters increased cumulatively from 2.5 at 6 months to 3.0 by 12 months (both p≤0.01). Median AHI reduction was 18.5 (2–27) (p=0.047). There were no statistically significant differences between OSA-alone and COMISA groups in HGNS adherence trajectories, therapy pauses, support needs, or AHI improvement (all p&gt;0.05). Conclusion Although HGNS use declined modestly over time, COMISA was not statistically associated with differences in adherence, clinical support needs, or treatment response. Directional trends suggest greater adaptation challenges among patients with COMISA, warranting evaluation in larger prospective studies. Support (if any)
0632 Retrospective Cohort Analysis of Diagnostic Polysomnography to Predict Treatment Response to Hypoglossal Nerve Stimulation in Obstructive Sleep Apnea
Dunn, Ryan , Goswami, Umesh, Yee, Claire, Truman, Mia, Tashman, Yasemin, Williams, Christopher, Morgenthaler, TI, Olson, Michael, Louis, Erik St, Colaco, Brendon, Bansberg, Stephen, Shandhi, Mobashir, Islam, Ariful, Lizak, Matt, Ruoff, Chad, Ruoff, Chad , Ruoff, Chad M , Tashman, Yasemin, LOUIS, ERIK ST., Colaco, Brendon, Bansberg, Stephen F. , Shandhi, Md Mobashir Hasan , Lizak, Matthew

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A281-A281

10.1093/sleep/zsag091.0631 Get It

Abstract Introduction Hypoglossal nerve stimulators (HGNS) are used in patients with moderate-to-severe obstructive sleep apnea (OSA) who are unable to tolerate or do not respond to continuous positive airway pressure (CPAP) therapy. However, a subgroup of patients fail to achieve resolution of OSA with HGNS alone. Previous studies have shown that lower BMI, lower nadir oxygenation, decreased sleep latency, and higher VOTE score on drug-induced sleep endoscopy (DISE) predict better treatment outcome. We hypothesize that baseline diagnostic polysomnography (PSG) may further predict which patients will achieve successful therapeutic outcome with HGNS therapy. Methods We conducted a retrospective analysis of all adult patients who underwent HGNS implantation at Mayo Clinic Arizona between 2019-2025 and had a pre-implantation diagnostic PSG available for review. Treatment success was defined by Sher Criteria: &gt;50% reduction in post-treatment apnea hypopnea index (AHI) to a final AHI of &lt; 20/hr. Responders met Sher criteria and non-responders did not meet Sher criteria. Demographics, sleep questionnaire results, PSG variables, and VOTE score on DISE were collected and analyzed using Spearman’s rank correlation of reduction in AHI. Results Twenty-three patients (11M/12F, median age: 69[IQR:64,75] years) met inclusion criteria. Median baseline AHI was 24[IQR:19,37]/hr. Median post-implant AHI was 8 [IQR:3, 14]/hr. Responders (n=15, 65%) and non-responders (n=8, 35%) demonstrated median post-implant AHI of 4.5[IQR:2.3,7.3]/hr and 15.7[IQR:12.3,28.5]/hr, respectively. Treatment response was associated with less time with SpO2 &lt; 88% (T88%) (21min [IQR:3,64] vs. 73[IQR:36,105mins]; p=0.023) and higher central apnea index (CAI) (1[IQR:0.1,3] vs. 0[IQR:0,1], p=0.03) on pre-implantation PSG. Conclusion In this small cohort of OSA patients, less nocturnal hypoxemia as defined by T88% and higher baseline central apnea index were predictors of better treatment response to HGNS therapy as measured by Sher criteria. We hypothesize that greater nocturnal hypoxemia likely reflects more severe airway obstruction during sleep. Our analysis also showed that responders had higher baseline CAI than non-responders, however we believe this association is not clinically significant and likely driven by one outlier (CAI 13/hr). Further analysis in a larger HGNS cohort is needed to confirm these findings. Data enrichment efforts and more sophisticated analyses are underway. Support (if any)